{
    "clinical_study": {
        "@rank": "119180", 
        "arm_group": {
            "arm_group_label": "rilpivirine hydrochloride", 
            "description": "Patients will be taking 1 tablet of 25 mg rilpivirine hydrochloride is administered once daily orally in combination with other anti-retroviral (ARV) medications."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and effectiveness of rilpivirine\n      hydrochloride in combination with other anti-retroviral (ARV) medications for the treatment\n      of ARV-naive (patients who have not been exposed to ARV) Filipino patients with human\n      immunodeficiency virus type 1 (HIV-1) infection."
        }, 
        "brief_title": "A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Human Immunodeficiency Virus Type 1 (HIV-1) Infection", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Virus Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (all people know the identity of the study medication), multi-center,\n      observational (study in which the investigators/ physicians observe the patients and measure\n      their outcomes) study. The total duration of the study will be 3 years, and approximately 60\n      patients who would use rilpivirine hydrochloride in routine clinical practice with a dosing\n      regimen stipulated in the product insert (ie, 25 mg once a day) will be enrolled. As this is\n      an observational study, assessment of patients will be based on the accepted clinical\n      practice in the Philippines. Patients will be monitored from baseline and throughout the\n      48-week (2nd, 4th, 8th, 12th, 24th, 36th and 48th weeks) treatment period of rilpivirine\n      hydrochloride."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Filipino patients\n\n          -  ARV naive patients with HIV-1 infection who are assessed by the physician to be\n             eligible for treatment with ARVs\n\n          -  Patients who voluntarily signed the informed consent form\n\n        Exclusion Criteria:\n\n          -  Patients receiving drugs known to prolong QTc intervals, medicinal products with a\n             known risk of Torsade de Pointes and anticonvulsants, systemic dexamethasone, proton\n             pump inhibitors\n\n          -  Any previous treatment for HIV\n\n          -  Previously documented HIV-2 infection\n\n          -  Patients with viral load of >100,000 HIV-1 ribo nucleic acid (RNA) copies/ml\n\n          -  Severely ill patients like those with acute acquired immune deficiency syndrome\n             (AIDS)-defining illness or other major concomitant - disease prior to enrolment\n\n          -  Patients with severe hepatic impairment\n\n          -  Known hypersensitivity to rilpivirine hydrochloride\n\n          -  Pregnant or breastfeeding females"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Filipino anti-retroviral (ARV) naive patients with human immunodeficiency virus type 1\n        (HIV-1) infection and who are using rilpivirine upon its local registration"
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692470", 
            "org_study_id": "CR100849", 
            "secondary_id": [
                "TMC278IFD4002", 
                "EDUPHLMA1"
            ]
        }, 
        "intervention": {
            "arm_group_label": "rilpivirine hydrochloride", 
            "description": "Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.", 
            "intervention_name": "No intervention", 
            "intervention_type": "Drug", 
            "other_name": "Edurant"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Human immunodeficiency virus type 1 (HIV-1) infection", 
            "HIV-1", 
            "Anti-retroviral naive", 
            "ARV", 
            "Filipino patients", 
            "Rilpivirine hydrochloride", 
            "Edurant"
        ], 
        "lastchanged_date": "September 24, 2013", 
        "number_of_groups": "1", 
        "official_title": "A Post-Marketing Surveillance Study on the Safety and Effectiveness of Rilpivirine Hydrochloride Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection", 
        "overall_official": {
            "affiliation": "Janssen Pharmaceutica", 
            "last_name": "Janssen Pharmaceutica Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Philippine: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of patients with incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From the date of first exposure of study medication until 30 days after the last exposure of the patient to the study medication, as assessed for 3 years"
            }, 
            {
                "measure": "Number of patients with incidence of discontinuation of study medication due to adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From the date of first exposure of study medication until 30 days after the last exposure of the patient to the study medication, as assessed for 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients who will not experience death due to acquired immune deficiency syndrome (AIDS) related events occurring after 6 months of treatment", 
                "safety_issue": "No", 
                "time_frame": "Week 24, 36 and 48"
            }, 
            {
                "description": "Virologic failure defined as a persistently detectable viral load in a patient with previously suppressed human immunodeficiency virus ribo nucleic acid (HIV RNA) or the inability to achieve an undetectable viral load after 24 weeks of therapy. The level of undetectable load is less than 50 HIV-1 RNA copies/ml.", 
                "measure": "Number of patients who will not develop virologic failure", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Week 1), Week 8, Week 24 and Week 48"
            }, 
            {
                "description": "Immunologic failure defined as either of the following conditions: a) CD4 count below 100 cells/mm3 after 6 months of therapy; b) return to or a fall below, the pre-therapy CD4 baseline after 6 months of therapy; c) a 50% decline from the on-treatment peak CD4 value (if known)", 
                "measure": "Number of patients who will not develop immunologic failure", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Week 1), Week 24 and Week 48"
            }, 
            {
                "description": "AIDS defining conditions may include: HIV wasting syndrome, pneumocystis jiroveci, recurrent severe bacterial pneumonia, chronic herpes simplex infection, esophageal candidiasis, extrapulmonary tuberculosis etc.", 
                "measure": "Number of patients who will not have emergence of new (ie, not present at baseline) AIDS defining conditions while on treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Week 1), Week 2, 4, 8, 12, 24, 36 and 48"
            }
        ], 
        "source": "Janssen Pharmaceutica", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Pharmaceutica", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013", 
        "why_stopped": "The company decided to cancel this study in conformity with Philippines FDA Circular 2013-004"
    }
}